Denali Therapeutics (DNLI) Return on Assets: 2018-2024
Historic Return on Assets for Denali Therapeutics (DNLI) over the last 7 years, with Dec 2024 value amounting to -0.30%.
- Denali Therapeutics' Return on Assets rose 7.00% to -0.30% in Q4 2024 from the same period last year, while for Dec 2024 it was -0.30%, marking a year-over-year increase of 7.00%. This contributed to the annual value of -0.33% for FY2024, which is 22.00% down from last year.
- Denali Therapeutics' Return on Assets amounted to -0.30% in Q4 2024, which was down 3.37% from -0.29% recorded in Q3 2024.
- Denali Therapeutics' Return on Assets' 5-year high stood at 0.05% during Q4 2020, with a 5-year trough of -0.37% in Q4 2023.
- Its 3-year average for Return on Assets is -0.28%, with a median of -0.28% in 2024.
- Examining YoY changes over the last 5 years, Denali Therapeutics' Return on Assets showed a top increase of 40bps in 2020 and a maximum decrease of 31bps in 2020.
- Over the past 5 years, Denali Therapeutics' Return on Assets (Quarterly) stood at 0.05% in 2020, then decreased by 26bps to -0.20% in 2021, then decreased by 4bps to -0.25% in 2022, then decreased by 12bps to -0.37% in 2023, then rose by 7bps to -0.30% in 2024.
- Its last three reported values are -0.30% in Q4 2024, -0.29% for Q3 2024, and -0.27% during Q2 2024.